Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients.
Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, Colafigli M, Tamburrini E, Cauda R, Silveri MC, Grima P, Di Giambenedetto S. Fabbiani M, et al. Among authors: ciccarelli n. HIV Med. 2013 Mar;14(3):136-44. doi: 10.1111/j.1468-1293.2012.01044.x. Epub 2012 Sep 21. HIV Med. 2013. PMID: 22994586 Free article.
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Di Giambenedetto S, et al. Among authors: ciccarelli n. J Antimicrob Chemother. 2013 Jun;68(6):1364-72. doi: 10.1093/jac/dkt007. Epub 2013 Jan 30. J Antimicrob Chemother. 2013. PMID: 23372058
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: ciccarelli n. Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28. Scand J Infect Dis. 2014. PMID: 24161018 Clinical Trial.
64 results